The Swiss drug giant Novartis is looking at alternate pricing models for its heart failure drug Entresto, which is expected to gain FDA approval in August.
The Swiss drug giant Novartis is looking at alternate pricing models for its heart failure drug Entresto, which is expected to gain FDA approval in August.
Proven to improve heart function in individuals with a reduced ejection fraction, Entresto, also called LCZ696, will probably earn significant annual revenue for Novartis, projected in the billions. However, according to David Epstein, division head of Novartis, the company is working with healthcare systems to introduce a new outcomes-based payment model, where the initial discounted rate will be balanced by increased payments to Novartis if the drug reduces hospital visits.
The healthcare industry is gradually moving towards such clinical-outcomes—based risk-sharing models, and Novartis has already has a system in place for this for it's multiple sclerosis drug Gilenya.
Read more at Reuters:
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Study Highlights BMP7 as a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More